ClinicalTrials.gg
RecruitingNCT07077057TITAN-OMIUpdated May 5, 2026

Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction

An interventional study of AI-assisted ECG interpretation (PMcardio) in Myocardial Infarction (MI) and Acute Coronary Syndrome (ACS), sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Cardiocentro Ticino · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.

Planned enrollment
22nd of 51
500 · median 334
Started
2025
with 2 others
No phase
24 of 69
6 open now
Primary completion
2027-08
later than 8 of 19 live
Registered
63rd of 69
by date

Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 22nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2025, is one of 24 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 63rd registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Myocardial Infarction with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria.

The main questions it aims to answer are:

  1. Does AI-assisted ECG interpretation enable more timely identification and treatment of OMI, as defined by earlier initiation of coronary intervention?
  2. Does AI-assisted diagnosis reduce infarct size, measured by peak high-sensitivity troponin T (hsTnT) levels?

Researchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines.

Participants will:

  1. Present with symptoms suggestive of ACS but without clear STEMI criteria
  2. Be randomized 1:1 to either AI-assisted or standard ECG interpretation
  3. Undergo follow-up assessments for cardiovascular outcomes, including 30-day death, time to treatment of total coronary occlusion, and peak hsTnT levels
03

Conditions studied

  • Myocardial Infarction (MI)
  • Acute Coronary Syndrome (ACS)

Keywords

  • Occlusion Myocardial Infarction
  • Electrocardiogram
  • Artificial Intelligence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder/arm/jaw/back, fatigue, or light-headedness
  2. Age: Patients aged 18 years or older.
  3. : Patients able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians.
  2. Pregnancy or Lactation.
  3. Legally incompetent to provide .
  4. Symptoms onset>24 hrs prior to clinical presentation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    AI-assisted ECG interpretation

    Participants will receive ECG interpretation supported by a CE-marked artificial intelligence (AI) tool (PMcardio, Powerful Medical). The AI output is made available to clinicians in real time, prior to diagnostic or therapeutic decisions, to facilitate earlier identification of occlusion myocardial infarction (OMI) and potentially expedite intervention.

    Diagnostic Test: AI-assisted ECG interpretation (PMcardio)

  • No intervention
    Standard of Care

    Participants will receive standard ECG interpretation without AI support. Clinical decisions regarding diagnosis and treatment will follow usual care pathways, without influence from the AI tool. This arm serves as the comparator to evaluate the added value of AI integration.

Interventions

  • Diagnostic testAI-assisted ECG interpretation (PMcardio)

    Participants in the experimental arm will undergo 12-lead ECG interpretation supported by a CE-marked artificial intelligence (AI) tool (PMcardio, Powerful Medical, Slovakia). The AI algorithm analyzes ECG data in real time to detect patterns suggestive of occlusion myocardial infarction (OMI), including cases not meeting traditional ST-elevation myocardial infarction (STEMI) criteria. In the experimental arm, the AI output is provided immediately to the treating clinician and used as an adjunct to standard ECG interpretation to support timely diagnosis and management decisions.

06

What researchers measure

Primary outcomes

  1. Hierarchical primary endpoint

    The primary endpoint of the prospective phase, analysed hierarchically using the unmatched, unstratified win ratio, will be a composite of: * Cardiovascular mortality at 30 days. * Timely treatment of angiographically confirmed TIMI 0-1 occlusions, defined as insertion of the arterial sheath within 120 minutes from randomization. * Time-to-treatment of angiographically confirmed TIMI 0-1 occlusions. * Peak high- hsTnT levels in ng/mL as a surrogate measure of infarct size. Time of coronary intervention will be defined as time from randomisation to insertion of the arterial sheath. Peak hsTnT is defined as the maximum level of hsTnT within 48h from randomization or within 48 hours from intervention if percutaneous coronary intervention took place later than 24 hours from randomization.

    Time frame: 30 days

Secondary outcomes

  1. Cardiovascular mortality at 30 days

    Cardiovascular mortality at 30 days

    Time frame: 30 days

  2. Timely treatment of TIMI 0-1 occlusions

    Timely treatment is defined as arterial sheath insertion within 120 minutes of randomization

    Time frame: Periprocedural

  3. Time-to-treatment of TIMI 0-1 occlusions

    Expressed in minutes from time of randomization

    Time frame: Periprocedural

  4. Peak hsTnT levels

    Peak hsTnT is defined as the maximum level of hsTnT within 48h from randomization or within 48 hours from intervention if percutaneous coronary intervention took place later than 24 hours from randomization.

    Time frame: 48 hours from randomization or intervention

  5. Major adverse cardiovascular events (MACE) at follow-up

    Major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, myocardial infarction, or stroke at follow up (30-days, 1 year, 3/5/10 years)

    Time frame: up to 10 years

  6. Cardiovascular death at follow-up

    Cardiovascular death at follow up (30-days, 1 year, 3/5/10 years)

    Time frame: up to 10 years

  7. Myocardial infarction at follow-up

    Myocardial infarction at follow up (30-days, 1 year, 3/5/10 years)

    Time frame: up to 10 years

  8. Stroke at follow-up

    Stroke at follow up (30-days, 1 year, 3/5/10 years)

    Time frame: up to 10 years

  9. Infarct Size

    • hsTnT area under the curve

    Time frame: 48 hours from randomization or intervention

  10. Infarct Size

    • Creatine kinase-MB (CK-MB) peak concentration

    Time frame: 48 hours from randomization or intervention

  11. Infarct Size

    • CK-MB area under the curve

    Time frame: 48 hours from randomization or intervention

  12. Time from randomization to antithrombotic therapy

    Time from randomization to antithrombotic therapy (expressed in minutes)

    Time frame: periprocedural

  13. Time from randomization to coronary angiography

    Time from randomization to coronary angiography (expressed in minutes) This outcome will be assessed both in all patients and in patients with OMI according to the different definitions.

    Time frame: periprocedural

  14. Angiographic outcomes (restricted to patients undergoing PCI)

    * Worst TIMI flow grade post-PCI (0-3) * Worst TIMI thrombus grade post-PCI (0-5)

    Time frame: Periprocedural

  15. Total time spent in the emergency department post-randomization

    Total time spent in the emergency department post-randomization

    Time frame: periprocedural

  16. Length of hospital stay post-randomization

    Length of hospital stay post-randomization (days)

    Time frame: up to 30 days

  17. Resource utilization

    Number of diagnostic tests and procedures performed post-randomization before coronary angiography, including troponin measurements, transthoracic echocardiography and stress testing

    Time frame: periprocedural

  18. Health economic outcomes

    These include both direct and indirect costs. Direct costs are defined as medical costs incurred post-randomization during the index hospitalization or emergency department visit, including diagnostics and procedures (e.g., ECG, troponin testing, coronary angiography, PCI), medications and consumables, staff time, and length of stay. Indirect costs, defined as non-medical or societal costs up to 30 days post-randomization, including lost productivity (e.g., time off work for patients or caregivers), transportation to follow-up visits, informal caregiving support, and early rehabilitation services

    Time frame: 30 days

  19. Safety (Serious adverse events)

    Time frame: up to 10 years

  20. Diagnostic accuracy of AI algorithm

    Restricted to patients in the control group: * Sensitivity * Specificity * Positive predictive value (PPV) * Negative predictive value (NPV)

    Time frame: periprocedural

  21. Quality of life (EuroQol 5-Dimension 5-Level [EQ-5D-5L] Index Score)

    Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) instrument at discharge and 30 days post-randomization. The EQ-5D-5L descriptive system comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five levels of severity. Responses are converted into a single index score using a country-specific value set. The index score typically ranges from values below 0 (worse than death) to 1 (full health), with higher scores indicating better health-related quality of life.

    Time frame: up to 30 days

Other outcomes

  1. Pre-procedural ECG analysis

    Sensitivity analysis of diagnostic accuracy of the AI-algorithm based on the 12-lead ECG recorded immediately prior to the start of coronary angiography, instead of the ECG at presentation.

    Time frame: periprocedural

  2. Alternative OMI definitions

    Sensitivity analysis of the primary outcome using an alternative definition of OMI: TIMI flow 0-1, or TIMI flow 2-3 in the presence of large thrombus burden (TIMI thrombus grade ≥3).

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

Access criteria: Reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 24 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 24 months is below that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 22, 2025
StartActual
Aug 23, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07077057
Lead sponsor
Cardiocentro Ticino
Responsible party
Marco Valgimigli (Deputy Chief of Cardiology, Cardiocentro Ticino) — Principal investigator
First posted
Jul 22, 2025
Start date
Aug 23, 2025
Primary completion
Aug 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion